https://scholars.lib.ntu.edu.tw/handle/123456789/527867
標題: | Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan | 作者: | HSIU-HAO CHANG YUNG-LI YANG Hung M.-H. Tasy W. MING-CHING SHEN |
公開日期: | 2007 | 出版社: | Scientific Communications International Ltd | 卷: | 106 | 期: | 4 | 起(迄)頁: | 281-287 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: The pharmacokinetic (PK) study of recombinant human factor IX (rFIX) has been done in patients with hemophilia B in areas other than Taiwan. However, wide patient-related variability in recovery is noted and there is no PK study of rFIX in Taiwanese patients with hemophilia B. The purpose of this study is to evaluate the PKs of the rFIX in Taiwanese patients with hemophilia B. Methods: A PK study of rFIX was performed in 10 previously treated Taiwanese patients with hemophilia B. Nine of them had severe hemophilia B and the other one had moderately severe hemophilia B. The mean age of our patients was 24.7 ± 8.6 years (mean ± SD) with a range of 15.5-47.0 years. Results: The infusion of 75 IU/kg of rFIX in our patients resulted in a mean FIX activity increase of 1.08 ± 0.27 IU/dL per IU/kg with a range of 0.3-1.49 IU/dL per IU/kg, and a mean in vivo recovery of 44.0 ± 9.5% with a range of 31.4-60.4%. The mean elimination half-life was 24.4 ± 6.4 hours with a range of 14.1-35.3 hours. The mean values of area under the curve, total body clearance, volume of distribution at steady state were 1363 ± 166IU × hour/dL, 4.84 ± 1.03 mL/hour/kg, and 144.3 ± 41.8 mL/kg, respectively. In addition, rFIX was well tolerated in our patients. Only two patients experienced mild treatment-related adverse events, including fever and feeling sleepy, respectively. Both of them resolved spontaneously without any sequences, and there was no thrombosis formation or inhibitor development in the following 6 months after rFIX infusion. Conclusion: The results of PK study of rFIX in our previously treated Taiwanese patients with hemophilia B are comparable to the reported results from other related studies conducted in different geographical areas. ? 2007 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34248659669&doi=10.1016%2fS0929-6646%2809%2960253-9&partnerID=40&md5=5bfc874ca6badcfc94adaf82b96135bc https://scholars.lib.ntu.edu.tw/handle/123456789/527867 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(09)60253-9 | SDG/關鍵字: | recombinant blood clotting factor 9; adolescent; adult; area under the curve; article; clinical article; controlled study; disease severity; distribution volume; drug clearance; drug distribution; drug elimination; drug fever; drug half life; drug infusion; drug response; drug tolerability; hemophilia B; human; in vivo study; laboratory test; maximum plasma concentration; physical examination; side effect; somnolence; steady state; Taiwan; thrombosis; vital sign |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。